Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
Sulfapyridine is an oral small-molecule sulfonamide antibiotic approved in 1939 for bacterial infections and inflammatory bowel conditions. The drug works by inhibiting bacterial folate synthesis, making it effective against susceptible gram-positive and gram-negative organisms. It has been used historically for rheumatoid arthritis and ulcerative colitis, though modern alternatives have largely superseded it.
As a legacy product with approaching loss of exclusivity and minimal competitive pressure (30%), the brand team is likely small and focused on managed care access rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on sulfapyridine offers limited career growth and visibility due to its legacy status, approaching LOE, and minimal linked job openings. This role is best suited for candidates seeking stable, low-intensity product stewardship or those transitioning to other assets within Eli Lilly's portfolio.
Worked on SULFAPYRIDINE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.